Advances in the management of diabetic kidney disease: beyond sodium-glucose co-transporter 2 inhibitors
Kidney Research and Clinical Practice
; : 682-698, 2022.
Artículo
en Inglés
| WPRIM (Pacífico Occidental)
| ID: wpr-967926
Biblioteca responsable:
WPRO
ABSTRACT
Progress in the treatment of diabetic kidney disease (DKD) has been modest since the early trials on renin-angiotensin-aldosterone system inhibitors (RAASis). Although sodium-glucose co-transporter 2 inhibitors (SGLT2is) have revolutionized the management of DKD by lowering proteinuria and protecting organs, other novel treatment approaches with good evidence and efficacy that can be used in conjunction with a RAASi or SGLT2i in managing DKD have emerged in the past few years. This review discusses the evidence for glucagon-like peptide-1 receptor agonist, selective mineralocorticoid receptor antagonist, and selective endothelin A receptor antagonist, emerging treatment options for DKD beyond SGLT2 inhibition.
Texto completo:
Disponible
Base de datos:
WPRIM (Pacífico Occidental)
Idioma:
Inglés
Revista:
Kidney Research and Clinical Practice
Año:
2022
Tipo del documento:
Artículo